WIP1 phosphatase as a potential therapeutic target in neuroblastoma

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Richter, Mark ^a   Dayaram, Tajhal ^b   Gilmartin, Aidan G ^a   Ganji, Gopinath ^a   Pemmasani, Sandhya Kiran ^c   Van Der Key, Harjeet ^a   Shohet, Jason M ^b   Donehower, Lawrence A ^b   Kumar, Rakesh ^a  

^a GLAXOSMITHKLINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Ocimum Biosolutions Ltd HUDA Techno Enclave ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CARBOPLATIN; CASPASE 3; CASPASE 7; CHECKPOINT KINASE 2; DOXORUBICIN; GSK 2830371; HISTONE H2AX; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1; AMINOPYRIDINE DERIVATIVE; DIPEPTIDE; GSK2830371; PROTEIN PHOSPHATASE 2C; TP53 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEUKEMIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROBLASTOMA CELL; OVERALL SURVIVAL; PPM1D GENE; TUMOR SUPPRESSOR GENE; ALLELE; ANTAGONISTS AND INHIBITORS; FEMALE; GENE LOCUS; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ALLELES; AMINOPYRIDINES; CELL LINE, TUMOR; DIPEPTIDES; FEMALE; GENETIC LOCI; HUMANS; MALE; MUTATION; NEUROBLASTOMA; PHOSPHOPROTEIN PHOSPHATASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922750547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115635     Document Type: Article

References (50)

1. Bruggeman SWM, Valk-Lingbeek ME, Van Der Stoop PPM, Jacobs JJL, Kieboom K, et al. (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19: 1438-1443. PMID: 15964995
2. Medrano S, Burns-Cusato M, Atienza MB, Rahimi D, Scrable H (2009) Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. Neurobiol Aging 30: 483-497. PMID: 17850928
3. Zhu Y-H, Zhang C-W, Lu L, Demidov ON, Sun L et al. (2009) Wip1 regulates the generation of new neural cells in the adult olfactory bulb through p53-dependent cell cycle control. Stem Cells 27: 1433-1442. doi: 10.1002/stem.65 PMID: 19489034
4. Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, et al. (2006) Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.Mol Carcinog 45: 594-604. PMID: 16652371
5. Lee JS, Lee MO, Moon BH, Shim SH, Fornace J, et al. (2009) Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells 27: 1963-1975. doi: 10.1002/stem.121 PMID: 19544416
6. Demidov ON, Timofeev O, Lwin HNY, Kek C, Appella E, et al. (2007) Wip1 Phosphatase Regulates p53-Dependent Apoptosis of Stem Cells and Tumorigenesis in the Mouse Intestine. Cell Stem Cell 1: 180-190. doi: 10.1016/j.stem.2007.05.020 PMID: 18371349
7. Zhu Y, Demidov ON, Goh AM, Virshup DM, Lane DP, et al. (2014) Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. J Clin Invest 124: 3263-3273. doi: 10.1172/JCI73015 PMID: 24911145
8. Le Guezennec X, Bulavin DV (2010) WIP1 phosphatase at the crossroads of cancer and aging. Trends in Biochemical Sciences 35: 109-114. doi: 10.1016/j.tibs.2009.09.005 PMID: 19879149
9. Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26: 7773-7779. PMID: 18066090
10. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. PMID: 15829956
11. Lu X, Nguyen TA, Zhang X, Donehower LA (2008) The Wip1 phosphatase and Mdm2: Cracking the Wip on p53 stability. Cell Cycle 7: 164-168. PMID: 18333294
12. Lu X, Nguyen TA, Donehower LA (2005) Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 4: 1060-1064. PMID: 15970689
13. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19: 1162-1174. PMID: 15870257
14. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, et al. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19 Arf pathway. Nat Gen 36: 343-350.
15. Li J, Yang Y, Peng Y, Austin RJ, Van Eyndhoven WG, et al. (2002) Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Gen 31: 133-134.
16. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Gen 31: 210-215.
17. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T, et al. (2006) The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 95: 257-263. PMID: 16254685
18. Fuku T, Semba S, Yutori H, Yokozaki H (2007) Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int 57: 566-571. PMID: 17685927
19. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, et al. (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neuro-Oncol 86: 245-256.
20. Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, et al. (2006) Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208: 554-563. PMID: 16400626
21. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, et al. (2005) Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23: 8853-8862. PMID: 16314645
22. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, et al. (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883. PMID: 12702577
23. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, et al. (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004. PMID: 12796361
24. Tan DSP, Lambros MBK, Rayter S, Natrajan R, Vatcheva R, et al. (2009) PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15: 2269-2280. doi: 10.1158/1078- 0432.CCR-08-2403 PMID: 19293255
25. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, et al. (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400. PMID: 17233815
26. Zhang L, Chen LH, Wan H, Yang R, Wang Z, et al. (2014) Exome sequencing identifies somatic gainof- function PPM1D mutations in brainstem gliomas. Nat Gen 46: 726-730. doi: 10.1038/ng.2995 PMID: 24880341
27. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, et al. (2013) Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493: 406-410. doi: 10.1038/ nature11725 PMID: 23242139
28. Kleiblova P, Shaltiel IA, Benada J, Sevcik J, Pechackova S, et al. (2013) Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 201: 511-521. doi: 10.1083/jcb. 201210031 PMID: 23649806
29. Barone G, Tweddle A, Shohet M, Chesler L, Moreno L, et al. (2014) MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets 15: 114-123. PMID: 24387312
30. Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, et al. (2009) Mdm2 deficiency suppresses MYCNdriven neuroblastoma tumorigenesis in vivo. Neoplasia 11: 753-762. PMID: 19649205
31. Kim E, Shohet J (2009) Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis. J Natl Cancer Inst 101: 1527-1529. doi: 10.1093/jnci/djp376 PMID: 19903809
32. Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F (2009) Escape from p53-mediated tumor surveillance in neuroblastoma: Switching off the p14ARF-MDM2-p53 axis. Cell Death Diff 16: 1563-1572. doi: 10.1038/cdd.2009.138 PMID: 19779493
33. Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, et al. (2014) Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol 10: 181-187. doi: 10.1038/nchembio.1427 PMID: 24390428
34. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593. doi: 10. 1038/nature10910 PMID: 22367537
35. Yamaguchi H, Minopoli G, Demidov ON, Chatterjee DK, Anderson CW, et al. (2005) Substrate specificity of the human protein phosphatase 2C(delta), Wip1. Biochemistry 44: 5285-5294. PMID: 15807522
36. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, et al. (2011) A Genome-Wide Search for Promoters That Respond to Increased MYCN Reveals Both New Oncogenic and Tumor Suppressor MicroRNAs Associated with Aggressive Neuroblastoma. Cancer Res 71: 3841-3851. doi: 10.1158/ 0008-5472.CAN-10-4391 PMID: 21498633
37. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681. PMID: 16968952
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. PMID: 16199517
39. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, et al. (2008) The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27: 123-135. doi: 10.1007/s10555-008-9127-x PMID: 18265945
40. Moon SH, Lin L, Zhang X, Nguyen TA, Darlington Y, et al. (2010) Wild-type p53-induced phosphatase 1 dephosphorylates histone variant (gamma)-H2AX and suppresses DNA double strand break repair. J Biol Chem 285: 12935-12947. doi: 10.1074/jbc.M109.071696 PMID: 20118229
41. Moon SH, Nguyen TA, Darlington Y, Lu X, Donehower LA (2010) Dephosphorylation of (gamma)H2AX by WIP1: An important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle 9: 2092-2096. PMID: 20495376
42. Seeger RC, Brodeur GM, Sather H (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 313: 1111-1116. PMID: 4047115
43. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, et al. (2010) High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res 16: 1108-1118. doi: 10.1158/1078-0432.CCR-09-1865 PMID: 20145180
44. Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, et al. (2011) Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3. Mol Cancer Ther 10: 983-993. doi: 10.1158/1535-7163.MCT-10-1090 PMID: 21460101
45. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, et al. (2009) Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53. J Natl Cancer Inst 101: 1562-1574. doi: 10.1093/jnci/djp355 PMID: 19903807
46. Castresana JS, Bello MJ, Rey JA, Nebreda P, Queizan A, et al. (1994) No TP53mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosomes Cancer 10: 136-138. PMID: 7520267
47. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, et al. (1993) Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53: 5269-5273. PMID: 8221661
48. Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H, et al. (1993) Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53: 4053-4058. PMID: 8358734
49. Belova GI, Demidov ON, Fornace J, Bulavin DV (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4: 1154-1158. PMID: 16258255
50. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, et al. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94: 6048-6053. PMID: 9177166